New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
10:49 EDTBMYBristol-Myers sees 'encouraging' trends for Eliquis with hopes of expansion
Expects to have data from third line Phase II study in squamous non-small cell lung cancer in first part of 2014. It will also continue to explore combinations as well as initiating first line Phase III monotherapy study. Bristol-Myers said assets in the U.S. are in a much better position entering 2014 for both commercial and Medicare Part D plans. Total commercial costs in 2014 are expected to increase from 2013 due to the diabetes transaction. Comments taken from Q4 earnings conference call.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
09:34 EDTBMYBarclays biopharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information
07:54 EDTBMYLeerink to hold a bus tour
Subscribe for More Information
05:48 EDTBMYBristol-Myers assumed with an Equal Weight at Barclays
Barclays analyst Geoff Meacham kept an Equal Weight rating on Bristol-Myers after assuming coverage of the name. He raised his price target for shares to $70 from $55.
November 30, 2015
15:15 EDTBMYBristol-Myers, AbbVie confirm FDA approval of Empliciti for multiple myeloma
Subscribe for More Information
10:26 EDTBMYFDA approves Empliciti to treat multiple myeloma
Subscribe for More Information
November 24, 2015
07:01 EDTBMYBristol-Myers announces EC approved reconciliation of indications for nivolumab
Subscribe for More Information
06:58 EDTBMYBristol-Myers announces FDA approval of Opdivo injection
Subscribe for More Information
November 23, 2015
19:29 EDTBMYBristol-Myers receives FDA approval for Opdivo
Subscribe for More Information
15:00 EDTBMYFDA approves Bristol-Myers drug to treat form of kidney cancer
Subscribe for More Information
November 18, 2015
12:01 EDTBMYBristol-Myers Squibb says Opdivo data shows 'superior' overall survival
Subscribe for More Information
08:11 EDTBMYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 17, 2015
10:47 EDTBMYBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use